TAP
Biosystems, a leading supplier of innovative automation and consumables for
life science applications today announced it is installing an advanced micro
bioreactor system (ambr
TM) system at The Georgia Institute of
Technology, a leading US research university.
The ambr
system, which closely replicates the characteristics
of bioreactors at micro scale, will be used by scientists in Georgia Tech's new
Stem Cell Engineering Center to determine optimal conditions for culturing
mouse and human pluripotent stem cell
lines, which could be used in drug discovery and cell therapy applications.
Additionally,
the ambr system will be used over a five year programme to help train at least 30
NSF (National Science Foundation) funded IGERT (Integrated Graduate Education
Research Training) trainees in stem cell production. This will allow these
researchers to understand how to scale and control stem cells into clinically
relevant numbers and will develop the next generation of experts in stem cell
biomanufacturing.
Dr
Todd McDevitt, Director of the Stem Cell Engineering Center at The
Georgia Institute of Technology said: "Manufacturing
stem cells in bioreactors is a goal for cost-effective production and to date we
have studied stem cell differentiation using rotary orbital suspension culture.
This type of culture method is not as practical for bioprocess modelling as it
is more time consuming and almost impossible to evaluate a wide range of media
and culture conditions in parallel."
Dr
McDevitt added: "Our research requires automation which offers a rigorous
approach and we initially considered developing our own equipment until we
heard about the ambr system. The ambr system is ideal for studying a large
number of parameters that could affect stem cell growth and differentiation and
we will use the ambr technology to predict stem cell performance in large scale
bioreactors."
Dr
Barney Zoro, ambr Product Manager at TAP Biosystems stated: "The cost of
generating many types of stem cell at clinically relevant scale is currently
prohibitive. Development of suspension culture processes will allow production of larger quantities
of more affordable stem cells and we're pleased that this
leading institute has chosen the ambr system to optimise these important stem
cell bioreactor cultures. Through their research, the ambr system could be instrumental in helping
to deliver cell lines for drug discovery assays, as well as enabling allogeneic
cell therapies to become more readily available."
For more info visit
www.tapbiosystems.com
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.